500,000 Shares in Perspective Therapeutics, Inc. (NYSE:CATX) Bought by Velan Capital Investment Management LP

Velan Capital Investment Management LP purchased a new position in Perspective Therapeutics, Inc. (NYSE:CATX) in the 4th quarter, Holdings Channel.com reports. The fund purchased 500,000 shares of the company’s stock, valued at approximately $1,595,000. Perspective Therapeutics accounts for about 1.4% of Velan Capital Investment Management LP’s investment portfolio, making the stock its 14th largest holding.

Other institutional investors have also added to or reduced their stakes in the company. Deerfield Management Company L.P. Series C increased its position in shares of Perspective Therapeutics by 4.3% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 2,938,754 shares of the company’s stock valued at $9,375,000 after acquiring an additional 120,991 shares during the period. Octagon Capital Advisors LP increased its holdings in Perspective Therapeutics by 62.1% during the 4th quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock valued at $7,352,000 after purchasing an additional 882,528 shares during the period. Nicholson Wealth Management Group LLC raised its position in Perspective Therapeutics by 0.4% during the 4th quarter. Nicholson Wealth Management Group LLC now owns 1,609,283 shares of the company’s stock valued at $5,134,000 after purchasing an additional 7,000 shares during the last quarter. Affinity Asset Advisors LLC raised its position in Perspective Therapeutics by 160.0% during the 4th quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company’s stock valued at $4,147,000 after purchasing an additional 800,000 shares during the last quarter. Finally, Millennium Management LLC purchased a new stake in Perspective Therapeutics in the 4th quarter worth approximately $4,132,000. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on CATX shares. Wedbush reaffirmed an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a research note on Tuesday, May 13th. Lifesci Capital raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th. Truist Financial reduced their price target on shares of Perspective Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, May 14th. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a report on Tuesday, March 4th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Perspective Therapeutics in a report on Monday, March 31st. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $12.50.

Perspective Therapeutics Stock Up 9.1%

Shares of CATX opened at $2.63 on Monday. The company has a 50 day simple moving average of $2.24 and a two-hundred day simple moving average of $3.59. Perspective Therapeutics, Inc. has a 1 year low of $1.60 and a 1 year high of $16.90.

Insider Buying and Selling at Perspective Therapeutics

In related news, CEO Johan M. Spoor purchased 22,026 shares of the company’s stock in a transaction that occurred on Friday, March 28th. The stock was bought at an average price of $2.24 per share, for a total transaction of $49,338.24. Following the completion of the transaction, the chief executive officer now owns 59,383 shares in the company, valued at approximately $133,017.92. The trade was a 58.96% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Robert F. Williamson III acquired 22,192 shares of the firm’s stock in a transaction on Friday, March 28th. The shares were bought at an average price of $2.27 per share, for a total transaction of $50,375.84. Following the completion of the transaction, the director now owns 70,837 shares of the company’s stock, valued at approximately $160,799.99. This trade represents a 45.62% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 115,696 shares of company stock valued at $256,344 in the last 90 days. Insiders own 3.72% of the company’s stock.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.